The FDA Struggle to Withdraw Makena
Daniel Aaron, I. Glenn Cohen, Eli Y. Adashi
Abstract
This Viewpoint discusses the controversy surrounding the FDA’s efforts to withdraw Makena from the market and the broader implications for the accelerated approval pathway.
Topics & Concepts
MedicineDrug approvalPharmacologyDrugPreterm Birth and ChorioamnionitisPregnancy and Medication ImpactReproductive Health and Contraception